Oncimmune website screenshot

Oncimmune

Oncimmune is a biotechnology company specializing in antibody and autoantibody biomarker discovery for precision medicine. Its proprietary ImmunoINSIGHTS platform screens against 9,000+ human antigens using Luminex xMAP bead-based multiplexed immunoassay technology, minimal sample volumes, high-throughput automated robotic workflows, and proprietary machine-learning algorithms to identify immune-system signatures across immuno-oncology, autoimmune disease, and infectious disease. Products include the ImmunoINSIGHTS 2K targeted panels, custom biomarker discovery services, and bioinformatics/data-science multiomics integration. Oncimmune was acquired by Alden Scientific in July 2025. The company operates as a research and discovery services provider and does not publish a public developer or API platform.

Oncimmune is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Precision Medicine, Biomarker Discovery, and Immuno-Oncology.

Oncimmune’s developer surface includes support and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyPrecision MedicineBiomarker DiscoveryImmuno-OncologyAutoantibodyDiagnosticsLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 8.9/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.8 / 17
Access Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.5 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/oncimmune: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: oncimmune
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/oncimmune.png
name: Oncimmune
description: Oncimmune is a biotechnology company specializing in antibody and autoantibody biomarker discovery for precision
  medicine. Its proprietary ImmunoINSIGHTS platform screens against 9,000+ human antigens using Luminex xMAP bead-based multiplexed
  immunoassay technology, minimal sample volumes, high-throughput automated robotic workflows, and proprietary machine-learning
  algorithms to identify immune-system signatures across immuno-oncology, autoimmune disease, and infectious disease. Products
  include the ImmunoINSIGHTS 2K targeted panels, custom biomarker discovery services, and bioinformatics/data-science multiomics
  integration. Oncimmune was acquired by Alden Scientific in July 2025. The company operates as a research and discovery services
  provider and does not publish a public developer or API platform.
url: https://raw.githubusercontent.com/api-evangelist/oncimmune/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- balderton-capital
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Precision Medicine
- Biomarker Discovery
- Immuno-Oncology
- Autoantibody
- Diagnostics
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.oncimmune.com/
- type: Support
  url: https://www.oncimmune.com/contact/
- type: PrivacyPolicy
  url: https://www.oncimmune.com/privacy-policy/
- type: TermsOfService
  url: https://www.oncimmune.com/terms-of-use/
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1